Project Grant R01AI200611
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $833K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10029, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Icahn School of Medicine at Mount Sinai $100,228 on November 15, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to map HIV reservoir establishment in human tonsil organoids. The research will characterize nonproductively infected cells—those harboring integrated HIV proviruses that express no viral proteins and thus evade clearance by antiviral treatments and the immune system—as a barrier to HIV...
- The National Institute of Allergy and Infectious Diseases awarded Icahn School of Medicine at Mount Sinai $838,493 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to optimize human cytomegalovirus neutralizing monoclonal antibodies as therapeutic biologics. The research characterizes pre-clinical parameters for developing human CMV neutralizing monoclonal antibodies targeting envelope proteins as therapeutics to inhibit CMV infection and...
- The National Institute of Allergy and Infectious Diseases awarded Icahn School of Medicine at Mount Sinai $156,510 on March 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on how hepatocytes and skeletal myocytes shape immunity to mRNA-lipid nanoparticle-encoded protein. The research addresses off-target mRNA uptake and expression in hepatocytes and skeletal myocytes during mRNA-LNP delivery. The investigator will engineer...
- The National Institute of Allergy and Infectious Diseases awarded Icahn School of Medicine at Mount Sinai $816,016 on August 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct mechanistic research on type 2 memory B cells and their role in allergy persistence. The research examines how germinal center-derived CD73+CD80+ IgG1 memory B cells generate high-affinity IgE plasma cells upon reactivation through sequential switching, and investigates human IgG...
- The National Institute of Allergy and Infectious Diseases awarded Icahn School of Medicine at Mount Sinai $209,128 on March 8, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to evaluate differences in innate immune response to highly pathogenic H5N1 viruses. The research tests the hypothesis that different H5N1 isolates exhibit different sensitivity to myxovirus resistance 1 (MX1) protein, a host restriction factor with demonstrated antiviral activity against...
- The National Institute of Allergy and Infectious Diseases awarded Albert Einstein College of Medicine $3.204 million on June 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to study the interaction between TAR RNA and INI1/SMARCB1, a component of the BAF chromatin remodeling complex, and its role in HIV-1 transcriptional regulation and latency reactivation. The research examines how INI1's winged helix DNA-binding domain binds to TAR RNA to facilitate...
- The National Institute of Allergy and Infectious Diseases awarded The Rockefeller University $2.373 million on June 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate mechanisms controlling HIV-1 latency and reservoir persistence in primary cells. The research develops and deploys a xenograft-based model system in NSG mice to generate human primary memory CD4+ T-cell populations containing latent HIV-1 proviruses with reporter genes. The work...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded Icahn School of Medicine at Mount Sinai $868,915 on September 1, 2026, for Project Grant R01AI193023 under the Allergy and Infectious Diseases Research program (CFDA 93.855). The research investigates the role of ANKEF1, a ciliary protein, in host defense against influenza virus infection. The work combines novel mouse models, human induced pluripotent stem cell-derived...
- The National Institute of Allergy and Infectious Diseases awarded Icahn School of Medicine at Mount Sinai $210,000 on August 7, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for Project Grant R21AI202288. The project investigates fate-mapping and genetic dissection of B-to-T feedback circuits shaping germinal-center selection. The work examines how transient CD70 expression in germinal-center B cells shapes antibody responses and the fates of both B and T...
- The National Institute of Allergy and Infectious Diseases awarded Albert Einstein College of Medicine a Project Grant totaling $1,486,296 on August 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into the human antibody response to Cryptococcus neoformans and survival outcomes in HIV-associated cryptococcal meningoencephalitis, a devastating opportunistic infection of the central nervous system that occurs predominantly in people...